Discussing the Future of Biotechnology with Bloomberg News
Bob Bradway
I’m excited to be leading Amgen as we harness dramatic advances in science and technology to serve patients suffering from serious diseases.
I spoke recently with Bloomberg News health correspondent Riley Griffin about the future of biotechnology in the post-COVID-19 era. While the pandemic has been devastating, it has also spurred unprecedented collaboration to develop new medicines for COVID-19. The lessons we’ve learned through this will serve us well as we battle heart disease, cancer, and the many other serious illnesses that affect tens of millions of people around the world. If you ever wanted proof that we’re living in the “biocentury,” COVID-19 provided it.
Click here to view my interview. Many thanks to the International Economic Forum of the Americas for organizing the exchange and for including it in the Forum’s ongoing “Conversation Series” with global business leaders.
#mycompany
Senior Oncology and Rare Disease Biopharmaceutical Sales Representative at Amgen: 2023 and 2022 Back to Back Chairman's Circle Winner.
3 年Very cool.
Medicine Should promote welbeing in a prima facie sense, without undesirable drug invade body system
3 年Visionary role model thinks holistically, understands the effects of time and therapist of minors. Rightly so a warrior of a mind to resolve issues we are facing now. Great intelligence and insights, thank you Amgen.
Medicine Should promote welbeing in a prima facie sense, without undesirable drug invade body system
3 年Valuable insights for healthier society, great vision and leadership! Truly inspirational.?